QIAGEN Commits to Reduce Carbon Emissions by Setting Science-Based Target to Reach Net Zero by 2050
09 November 2021 - 8:05AM
Business Wire
- Joins “Business Ambition for 1.5˚C” campaign of the
Science-Based Targets initiative
- Commitment to achieve by 2030 at least 40% reduction in Scope 1
and 2 emissions, and at least 10% reduction in Scope 3 emissions,
on way to reach net-zero carbon emissions by 2050
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today
announced its commitment to a science-based target of net-zero
carbon emissions by 2050 in order to help limit global warming to
1.5˚C. This move supports the goals set out by the Paris Climate
Agreement and marks an important milestone in QIAGEN’s
sustainability efforts.
QIAGEN’s ambition to reach net-zero by 2050 applies to its
entire value chain and fulfills the criteria of the Science-Based
Targets initiative (SBTi), a partnership between the non-profit
disclosure specialist CDP, United Nations Global Compact (UNGC),
World Resources Institute (WRI) and World Wide Fund for Nature
(WWF).
The commitment calls for QIAGEN by 2030 to reduce Scope 1 and 2
emissions by at least 40% and Scope 3 emissions by at least 10% on
the way to reaching net-zero carbon emissions by 2050 using 2020 as
a baseline.
QIAGEN is joining more than 2,000 companies and other groups in
the United Nations’ Race to Zero Campaign anchored through SBTi’s
“Business Ambition for 1.5˚C” initiative.
“Our commitment strengthens QIAGEN’s ambition to reduce carbon
emissions and do our part to hold global warming to 1.5˚C compared
to pre-industrial times. Helping to create a sustainable future is
at the core of our vision of making improvements in life possible,”
said Thierry Bernard, Chief Executive Officer of QIAGEN N.V.
“Social and environmental responsibility are vital to our business.
In pledging to become carbon neutral by 2050, we are taking these
commitments to the next level and embedding environmental
sustainability in everything we do.”
QIAGEN plans to achieve net zero status by cutting direct and
indirect emissions throughout its operations. This goal is planned
to be achieved through a series of measures - including
transitioning facilities to renewable energy, implementing
energy-saving measures, minimizing waste in operations, factoring
carbon footprints into product development, and working with
suppliers and logistical operators to reduce their carbon
footprints.
A shrinking carbon footprint is just one key aspect of QIAGEN’s
sustainability initiatives, which are reflected in QIAGEN having a
PRIME rating from ISS ESG. Other aspects include a pledge to cut
plastic use in packaging for products, a steadfast dedication to
being socially responsible toward communities, and unwavering
support for creating a diverse and inclusive working
environment.
“Factoring social and environmental problems into day-to-day
business is not about putting up with them as best-avoided costs
that only add to the price of doing business,” said Dr. Angelika
Storm, Head of ESG Strategy and Impact Programs at QIAGEN. “It is
about recognizing them as an investment into being able to continue
operating as a company.”
For more information on QIAGEN’s sustainability initiatives,
please visit our website at
https://www.qiagen.com/us/sustainability.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (primarily forensics), Pharma (pharma and biotech
companies) and Academia (life sciences research). As of September
30, 2021, QIAGEN employed approximately 6,000 people in over 35
locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be
considered forward-looking statements within the meaning of Section
27A of the U.S. Securities Act of 1933, as amended, and Section 21E
of the U.S. Securities Exchange Act of 1934, as amended. To the
extent that any of the statements contained herein relating to
QIAGEN's products, collaborations markets, strategy or operating
results, including without limitation its expected adjusted net
sales and adjusted diluted earnings results, are forward-looking,
such statements are based on current expectations and assumptions
that involve a number of uncertainties and risks. Such
uncertainties and risks include, but are not limited to, risks
associated with management of growth and international operations
(including the effects of currency fluctuations, regulatory
processes and dependence on logistics), variability of operating
results and allocations between customer classes, the commercial
development of markets for our products to customers in academia,
pharma, applied testing and molecular diagnostics; changing
relationships with customers, suppliers and strategic partners;
competition; rapid or unexpected changes in technologies;
fluctuations in demand for QIAGEN's products (including
fluctuations due to general economic conditions, the level and
timing of customers' funding, budgets and other factors); our
ability to obtain regulatory approval of our products; difficulties
in successfully adapting QIAGEN's products to integrated solutions
and producing such products; the ability of QIAGEN to identify and
develop new products and to differentiate and protect our products
from competitors' products; market acceptance of QIAGEN's new
products and the integration of acquired technologies and
businesses. For further information, please refer to the
discussions in reports that QIAGEN has filed with, or furnished to,
the U.S. Securities and Exchange Commission (SEC).
Category: Corporate
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211108006066/en/
QIAGEN Investor Relations John Gilardi, +49 2103
29 11711 Phoebe Loh, +49 2103 29 11457 ir@QIAGEN.com
Public Relations Thomas Theuringer, +49 2103 29 11826
Robert Reitze, +49 2103 29 11676 pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024